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Tolerance to the foetal ‘allograft’ has been extensively
studied in the past few years, providing interesting new
insights. In addition to a potential role for HLA-G, which has
been widely discussed, there are hypotheses suggesting
roles for several other molecules or cells: leukemia inhibitory
factor and its receptor; indoleamine 2.3-dioxygenase; the
Th1/Th2 balance; suppressor macrophages; hormones such
as progesterone or the placental growth hormone; CD95
and its ligand; and, as recently proposed, annexin II.
Tolerance of the foetal allograft is probably the consequence
of a wide panel of mechanisms that may or may not be
pregnancy-specific, that are of major or secondary
importance and that may be interconnected.
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Abbreviations
CD95-L CD95-ligand
hPGH human placental growth hormone
IDO indoleamine 2,3-dioxygenase
KIR killer-cell immunoglobulin-like receptor
LIF leukemia inhibitory factor
LIF-R LIF-receptor
Introduction: tolerance to the foetus
The conceptus genome is half-paternal and half-maternal.
It is thus logical to presume that the immune system of the
mother should reject it, as it does every paternal graft [1],
but this generally does not occur. Tolerance of the semi-
allogenic foetal ‘graft’ by the maternal immune system is a
medical enigma that has stimulated research for half a cen-
tury. Indeed, in 1953 Billingham and Medawar published
an article in Nature in which this question was discussed [2].
Four hypotheses were proposed by the authors: that the
conceptus lacked immunogenicity; that there was a signifi-
cant lowering of immune response during pregnancy; that
the uterus is an immunoprivileged site; and that there is the
elaboration of an immune barrier by the placenta.
Through the years, the first three hypotheses have been
abandoned. Indeed, studies of Hoskin and Murgita [3]
revealed an immune reaction against foetal cells in the
mouse and showed that the conceptus possesses immuno-
genic properties. Medical observations of pregnant women
and studies of their immune status and of the response of
their immune cells to various stimuli proved that the
immune response of pregnant women is not significantly
reduced in comparison with that of non-pregnant women.
Finally, the possibility of ectopic pregnancies demon-
strates that the uterus does not uniquely protect the
conceptus as an immunoprivileged site.
The fourth hypothesis, suggesting the existence of an
immune barrier elaborated by the placenta, is still consid-
ered — but in another form. Originally, this barrier was
presumed to be passive or neutral but later, as reviewed by
Petraglia et al. [4], the placenta was shown to be a site of
active tolerance. Therefore, tolerance to the semi-allogenic
foetus by the maternal immune system seems mainly an
active mechanism whereby foetal tissues are prevented
from being recognised as foreign tissue and/or from being
rejected by the cells of the maternal immune system. In
this article, we summarise ten factors that have been
advanced as candidates in hypotheses to explain this phe-
nomenon. Their order reflects to a large extent how
established their roles have become.
Hypotheses to explain maternal tolerance of
the foetus
Since half of the foetal genome derives from the father, the
foetus synthesises antigens considered to be foreign by the
maternal immune system [1]. Furthermore, foetal cells, and
thus potentially immunogenic foetal antigenic molecules,
may be detected in the maternal blood [5]. It is presumed
that these cells and molecules are released into the mater-
nal blood during proliferation of trophoblastic cells,
following tissue ruptures that occur at the terminal extrem-
ity of the growing chorial villi. The whole immune system
comes into contact with these potential foetal immunogens
and, in spite of this, the conceptus is tolerated and preg-
nancy reaches its term without any major immunological
problem in the greatest majority of cases. Nevertheless,
Hoskin and Murgita [3] have shown that splenocytes of
primiparous mice proliferate following exposure to foetal
cells whereas those of virgin mice do not. This indicates
that, in the mouse, the maternal immune system is poten-
tially able to recognise and react against foetal antigens.
During normal pregnancy, however, this response capacity
does not have negative consequences.
So we are confronted with a two-tiered regulatory system:
firstly, effects occur on the whole maternal immune sys-
tem, probably and principally mediated through soluble
endocrine factors; secondly, at a local level, effects occur
during the direct contact of maternal and foetal cells in the
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placenta, principally through cellular contacts, or paracrine
and autocrine soluble factors.
The ten factors that we outline below, and the resulting
hypotheses concerning their role in the phenomenon of
tolerance to the foetal allograft, seem to implicate different
mechanisms working in synergy.
HLA-G expression by the trophoblast
In humans, the syncytiotrophoblast, which constitutes
the foetal syncytial layer isolating the foetal tissues from
the maternal tissues, expresses a very particular set of
MHC class I molecules. Indeed, HLA-A and HLA-B are
not presented by the syncytiotrophoblastic cells whereas
HLA-C seems weakly expressed [6,7]. On the other
hand, these cells express HLA-G ([8]; see also Update);
this class I molecule is encountered only on the syncy-
tiotrophoblast and is nearly monomorphic — only two
forms of this molecule are currently known. Recently,
HLA-G has been found to bind the KIRs (killer-cell
immunoglobulin-like receptors) of NK cells, as the other
HLA molecules do. This interaction appears to block the
cytotoxicity of these cells (Figure 1) and may contribute
to the tolerance of the conceptus by reducing NK cell
activity [9]. The nearly monomorphic status of HLA-G
suggests a general inhibition of NK cells, independent of
the parental genomes.
Leukemia inhibitory factor and its receptor
The maternal endometrium synthesises and secretes a
hydrosoluble molecule called leukemia inhibitory factor
(LIF) following a menstrual cycle related to the proges-
terone cycle [10]. During implantation, the endometrium
secretes LIF whereas the blastocyst expresses at its surface
the LIF-receptor (LIF-R) [11,12] (Figure 2a). This is
absolutely required for blastocyst implantation. During
pregnancy, LIF is synthesised by the decidua — the
maternal part of the placenta — and by Th2 lymphocytes
whereas the syncytiotrophoblast expresses LIF-R [13]
(Figure 2b). The exact function of the LIF/LIF-R mole-
cules during pregnancy is still unknown but the binding of
LIF on its receptor might favour trophoblastic growth and
differentiation [14]. This mechanism is also closely related
to other immune mechanisms implicated in the foeto-
maternal tolerance, such as the Th1/Th2 balance and
regulation by progesterone.
Indoleamine 2,3-dioxygenase
Indoleamine 2,3-dioxygenase (IDO) is an enzymatic pro-
tein that catabolises tryptophan. This enzyme is
synthesised and secreted by the syncytiotrophoblast and
has been shown to be essential for the success of pregnan-
cy in the mouse [15,16]. A proposed explanation for its role
in tolerance of the foetus is that IDO could act by
catalysing tryptophan destruction in maternal immune
cells that are localised in the placental area; this tryptophan




A potential role of HLA-G in tolerance to the foetus. HLA-G, which is
expressed specifically by the syncytiotrophoblast, may inhibit maternal
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Figure 2
A potential role of LIF and its receptor in tolerance to the foetus.
(a) During implantation, LIF is secreted by the endometrium and allows
the LIF-R-expressing blastocyst to implant. (b) During pregnancy, LIF
is synthesised by the decidua and Th2 cells. Its binding to
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The Th1/Th2 balance
Th0 precursor cells differentiate into Th1 or Th2 cells in
response to signals given during antigen presentation. In
the presence of IL-12 and IFN-γ, Th0 cells will differenti-
ate into Th1 cells; in contrast, Th0 cells become Th2 cells
after contact with IL-4 [17].
The Th1/Th2 balance in the placenta has been studied
and results have shown that a Th1-type reaction in the pla-
centa, which mainly generates inflammatory responses, is
often correlated with miscarriages whereas a Th2 cell
induction generates noninflammatory responses that are
compatible with the survival of the foetus [13,18–20]. Th1
and Th2 cells exert different actions. Th1 cells synthesise
IL-2 and IFN-γ whereas Th2 cells preferentially synthe-
sise IL-4, IL-5, IL-6, IL-9, IL-10 (see also Update) and
IL-13. Th1 and Th2 cells also share the production of
some cytokines like IL-3, TNF and GM-CSF.
T cells are, however, not the only producers of cytokines.
Notably here, syncytiotrophoblasts and cytotrophoblasts
are able to produce cytokines; these cells can also influ-
ence cytokine production, by acting on Th1/Th2 balance
[21,22]. They generally direct to a Th2-type response in
the peri-implantatory site of the endometrium [23] and
during pregnancy (Figure 4) [24].
Suppressor macrophages
Placental macrophages that protect the immunologically
privileged embryo occur naturally [25]. Today these suppres-
sor macrophages are considered to be ‘alternatively’
activated macrophages that are able to exert anti-inflamma-
tory influences in various sites of the body. In contrast to
‘classically’ activated macrophages that have pro-inflamma-
tory potency, for example those induced by IFN-γ or
lipopolysaccharides, the alternatively activated macrophages
produce little to no free oxygen derivatives but produce
more of the anti-inflammatory molecules IL-10 and IL-1-R-
antagonist (see [26] for a review).
Hormones
Numerous hormones and cytokines are present and active
at the placenta (for a review, see [4]). They act on the tro-
phoblastic tissues in many ways and some of them
modulate immune functions.
An important molecule is progesterone, which is synthe-
sised in large quantities by the placenta and is able to lower
the immune response [27]. The precise effects of this hor-
mone on foetal tolerance have been described. Progesterone
is able to promote LIF synthesis by the endometrium [10]
and to displace the Th1/Th2 balance (see above) towards
Th2 [28] (Figure 4); however progesterone is not the only
hormone able to act on the immune system.
Growth hormone appears likewise, in some rodent
species, to influence certain functions of the immune
system. It is important to note that the human placenta
synthesises a particular growth hormone, human placen-
tal growth hormone (hPGH), differing in only 13 amino
acids from pituitary growth hormone (hGH-N); hPGH
replaces hGH-N in the maternal blood during the sec-
ond half of the pregnancy [29,30]. hPGH is abundantly
produced during pregnancy and could play an active role
in foeto-placental tolerance by acting on the maternal
immune system. Experiments in which hGH-N or
hPGH were introduced at physiological concentrations
into the culture medium of lymphoid cells indicated that
the actions of hGH-N and hPGH on cell proliferation
and the production of cytokines are equivalent [31].
Because of its structural, binding and physiological dif-
ferences relative to hGH-N, it is possible that
hPGH-specific effects may be found in the future, both
in vitro and in vivo.
Foetal tolerance mechanisms Thellin et al. 733
Figure 3
A potential role of IDO in tolerance to the foetus. Syncytiotrophoblastic
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Figure 4
A potential role of the Th1/Th2 balance in tolerance to the foetus. A
successful pregnancy is more often correlated with a Th2- than with a
Th1-type neighbourhood. Besides, the syncytiotrophoblast secretes
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CD95 and its ligand
The CD95/CD95-ligand (CD95-L) system is an apoptotic
pathway widely used in the immune system during lym-
phopoiesis and immunopoiesis. It is mainly implicated in
regulation of cellular turnover, tumor cell elimination,
antiviral responses and protection of particular tissues
against potential danger represented mainly by activated
lymphocytes [32]. It is also active during clonal deletion of
autoimmune cells inside the central and peripheral lym-
phoid organs and is involved in the cytolytic pathways of
NK cells, Th1 cells and cytotoxic T cells. This cytolysis
occurs in parallel with perforin production by NK cells and
cytotoxic T cells.
This system functions as follows: CD95-L is expressed by
effector cells whereas the target cells express CD95. For
protection of particular tissues, CD95-L is expressed by
the cells that delineate the immunoprivileged site. For
example, CD95/CD95-L are active in the protection of
certain parts of the eye [33,34] and CD95-L has been
detected on the surface of rat Sertoli cells [35] and, more
recently, inside human testis [32]. We and other groups
have proposed that CD95-L is expressed by trophoblastic
cells and is able to kill the activated, CD95+ blood cells
that enter into contact with the conceptus (Figure 5).
In parallel with other groups [32,36], we have indeed
shown that trophoblastic cells synthesise CD95-L in vivo
and in vitro [37]. Cultured trophoblastic cells are able to
induce apoptosis in blood T cells expressing CD95 [38]. It
is notable that trophoblastic cells also express CD95 ([39];
O Thellin, B Coumans, E Heinen, unpublished data) but
apparently do so without full apoptotic consequences for
these cells [40]. This CD95 expression could play a role in
limiting the proliferation of the trophoblast. Our results
also suggest that only a part of the observed apoptosis
occurs effectively via the CD95/CD95-L pathway; the
TNF/TNF-R apoptotic system, which is also present at
the placenta [4], could be involved in tolerance to the foe-
tus. By in vivo observation, Jerzak et al. [41] detected
apoptotic T lymphocytes in human decidua during the
first trimester; this supports our hypothesis related to the
active elimination of potentially dangerous T cells by tro-
phoblastic cells.
Furthermore, proteolysis of cell surface CD95-L, medi-
ated by a membrane metalloproteinase, produces a
26 kDa soluble form of the CD95-L [42–44]. This mole-
cule is biologically active [45] and could also trigger
apoptosis of immune cells near to, or coming into contact
with, the foetal cells.
Annexin II
Annexin II is a member of a family of glycoproteins that
bind to negatively charged phospholipids in a calcium-
dependent manner. Annexins are membrane-associated
proteins that are expressed in both normal and malignant
cells and can also be secreted by the placenta [46].
Recently, Aarli and Matre [47] showed that annexin II can
partially inhibit lymphoproliferation of, and IgG and IgM
secretion by, maternal immune cells (Figure 6). Thus, this
molecule might be involved in protection of the foetus
against the maternal immune system.
Lowered complement activity
A way commonly used by the immune system to kill foreign
or cancerous cells is to activate the complement system.
Certain antibody isotypes bind to their membrane antigen
and initiate the complement cascade, leading to the assem-
bly of the membrane attack complex; this creates a hole in
the target cell, which then dies quickly. So, recognition of
paternal antigens on the surface of syncytiotrophoblast
could activate the complement cascade, resulting in death of
trophoblastic cells. Certain molecules are able to reduce this
phenomenon, either by blocking the binding sites of the
complement to antibodies (e.g. membrane complement
protein [MCP] does this) [48] or by raising the complement
destruction rate (e.g. decay accelerating factor [DAF] does
this) [49] (Figure 7). These molecules have systemic effects.
In the placenta, they could reduce the ability of comple-
ment to kill trophoblastic cells that bear paternal antigens
(see also Update).
Hidden trophoblastic antigens
It has been suggested that trophoblastic antigens expressed
by the syncytiotrophoblast are camouflaged, thus avoiding
the maternal immune system [50]; however, this hypothe-
sis is very speculative. There are numerous possibilities for
the mechanism of camouflage, including foetal-antigen-
specific blocking antibodies and fibrinoid material or
sialomucines, which may ‘cover’ foetal antigens. Anti-idio-
typic antibodies that block antibodies directly aimed at the
foetal antigens could also be implicated [51]. Hiding of the
trophoblastic antigens suggests a reduction of the anti-
genicity of the syncytiotrophoblast.
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Figure 5
A potential role of CD95 and its ligand in tolerance to the foetus.
Syncytiotrophoblastic CD95-L binds CD95 on maternal immune cells,
which triggers their apoptosis; in contrast, binding of CD95 to its
ligand on the syncytiotrophoblast does not appear to cause apoptosis
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Conclusions
As reviewed here, many very different mechanisms play a
part in foeto-placental tolerance; however, their relative
importance in other aspects of pregnancy may differ. Indeed,
progesterone and LIF/LIF-R are necessary for blastocyst
implantation. Progesterone also plays a major role during
implantation and gestation; it can act locally and at a distance.
Other mechanisms, such as those involving IDO, HLA-G,
CD95/CD95-L and the complement-inhibiting molecules
exert their effects primarily on the immune system.
The factors outlined above involve one molecule that is only
found at the placenta (HLA-G) whereas other mechanisms
act elsewhere in the organism (complement regulation,
IDO, Th1/Th2, certain hormones, CD95/CD95-L and
annexin II; see also Update).
These mechanisms mainly work in parallel but some of
them could also help to restrain negative effects of other
ones. For example, CD95-L acts as chemotactant for the
granulocytes [52] (this could explain how these cells are
mobilized against CD95-L-expressing grafts [53,54])
whereas pituitary growth hormone has been shown to
inhibit the chemotaxis of neutrophils [55]. hPGH, which is
produced in high amounts by the foetal part of the placen-
ta, may protect the foetal tissues against an invasion by
maternal neutrophils that are attracted by CD95-L. The
redundant mechanisms that are involved in tolerance to
the conceptus allow successful pregnancy even when
women are deficient for one of these mechanisms. 
In summary, maternal tolerance of the foeto-placental graft
is the result of the integration of numerous mechanisms of
various origins and modes of action; however only some of
these mechanisms may really be important for the success
of the pregnancy.
Update
Recently, the anti-inflammatory cytokine IL-10, produced
notably in the placenta, has been shown to increase HLA-G
synthesis in vitro in peripheral-blood monocytes and in tro-
phoblast organ culture, and is thus a good candidate as a
stimulator of HLA-G synthesis in the trophoblast in vivo [56].
Regulation of complement could be more important than
previously expected, as mice with a knockout of Crry (a
rodent-specific complement regulator) die in utero. These
embryos appear to contain C3 deposited on the placenta,
indicating complement activation ([57]; see [58] for review).
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